FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120564211> ?p ?o ?g. }

• W3120564211 abstract "Background: Infective endocarditis (IE) is a relatively rare disease but with significant rates of morbidity and mortality. The goal of IE treatment is to eradicate the foci of infection, including antimicrobial therapy with or without surgery. The decision on the selection of an empirical therapy regimen is diverse and based on patient characteristics. Vancomycin and teicoplanin are bacteriostatic glycopeptide antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, including MRSA-IE, and patients allergic to penicillin who are infected with methicillin-sensitive Staphylococcus aureus. Objective: The current study aimed to compare the efficacy and adverse effects of vancomycin and teicoplanin in the treatment of patients with MRSA-IE. Materials and Methods: This parallel, randomized, and controlled trial study was carried out on the efficacy and safety of teicoplanin versus vancomycin in the treatment of MRSA endocarditis within August 2012 and April 2017. The present study recruited adult patients with a definite or possible diagnosis of IE based on the Modified Duke Criteria. A central computer-generated random number list was used to allocate the patients (1:1) to the treatment with teicoplanin or vancomycin. Vancomycin was intravenously administered at a dose of 30 mg/kg/day in two doses. Teicoplanin was administered at a loading dose of 6-12 mg/kg every 12 h in four doses and then continued once a day. Results: Out of 86 patients screened with suspected IE, 66 patients were randomly assigned to the vancomycin (n=33) and teicoplanin (n=33) groups. The mean age values of the study subjects were 41±11.8 and 39±13.1 years in the vancomycin and teicoplanin groups, respectively. In addition, 27 patients (81.8%) in the vancomycin group met the criteria for microbiological cure, compared to 25 subjects (89.3%) in the teicoplanin group. In this regard, the observed difference was not statistically significant (P=0.41). Moreover, 26 (78.8%) and 23 (82.1%) patients in the vancomycin and teicoplanin groups achieved clinical cure, respectively (P=0.97). Overall, the patients in the vancomycin group experienced more adverse events in comparison to those of the teicoplanin group (P=0.04). The rate of acute kidney injury over time, especially in the first week of therapy, was higher in the vancomycin group than that reported for the teicoplanin group (P=0.05). Six and four patients in the vancomycin and teicoplanin groups required dialysis, respectively. The use of dialysis was not different between the two groups (P=0.88). Seven (21.3%) and five (17.9%) patients in the vancomycin and teicoplanin groups died, respectively, which was not statistically different between the two groups (P=0.74). Conclusions: It was concluded that the administration of vancomycin or teicoplanin does not significantly change the outcome of patients undergoing empirical treatment for MRSA-IE. This finding indicates the patients are similar in clinical outcomes and mortalities despite some adverse effects, such as skin rashes; therefore, teicoplanin can be considered a treatment choice for these diseases." @default.
• W3120564211 created "2021-01-18" @default.
• W3120564211 creator A5008198825 @default.
• W3120564211 creator A5015210829 @default.
• W3120564211 creator A5026340422 @default.
• W3120564211 creator A5035831300 @default.
• W3120564211 creator A5049362679 @default.
• W3120564211 creator A5054306438 @default.
• W3120564211 creator A5068446204 @default.
• W3120564211 creator A5080246819 @default.
• W3120564211 date "2020-12-07" @default.
• W3120564211 modified "2023-10-16" @default.
• W3120564211 title "A Randomized Controlled Clinical Trial on Therapeutic Effects of Teicoplanin and Vancomycin after Cardiac Surgery due to MRSA infective endocarditis in ICU Patients" @default.
• W3120564211 cites W1905008412 @default.
• W3120564211 cites W1920355337 @default.
• W3120564211 cites W1967300023 @default.
• W3120564211 cites W2032807806 @default.
• W3120564211 cites W2073651855 @default.
• W3120564211 cites W2081623389 @default.
• W3120564211 cites W2097950056 @default.
• W3120564211 cites W2118454836 @default.
• W3120564211 cites W2135173846 @default.
• W3120564211 cites W2156451821 @default.
• W3120564211 cites W2182541611 @default.
• W3120564211 doi "https://doi.org/10.32592/ircmj.2021.23.1.69" @default.
• W3120564211 hasPublicationYear "2020" @default.
• W3120564211 type Work @default.
• W3120564211 sameAs 3120564211 @default.
• W3120564211 citedByCount "0" @default.
• W3120564211 crossrefType "journal-article" @default.
• W3120564211 hasAuthorship W3120564211A5008198825 @default.
• W3120564211 hasAuthorship W3120564211A5015210829 @default.
• W3120564211 hasAuthorship W3120564211A5026340422 @default.
• W3120564211 hasAuthorship W3120564211A5035831300 @default.
• W3120564211 hasAuthorship W3120564211A5049362679 @default.
• W3120564211 hasAuthorship W3120564211A5054306438 @default.
• W3120564211 hasAuthorship W3120564211A5068446204 @default.
• W3120564211 hasAuthorship W3120564211A5080246819 @default.
• W3120564211 hasBestOaLocation W31205642111 @default.
• W3120564211 hasConcept C126322002 @default.
• W3120564211 hasConcept C141071460 @default.
• W3120564211 hasConcept C168563851 @default.
• W3120564211 hasConcept C174802600 @default.
• W3120564211 hasConcept C197934379 @default.
• W3120564211 hasConcept C2775872228 @default.
• W3120564211 hasConcept C2776703206 @default.
• W3120564211 hasConcept C2777052132 @default.
• W3120564211 hasConcept C2778980435 @default.
• W3120564211 hasConcept C2779489039 @default.
• W3120564211 hasConcept C2780176578 @default.
• W3120564211 hasConcept C2781413609 @default.
• W3120564211 hasConcept C501593827 @default.
• W3120564211 hasConcept C523546767 @default.
• W3120564211 hasConcept C54355233 @default.
• W3120564211 hasConcept C71924100 @default.
• W3120564211 hasConcept C86803240 @default.
• W3120564211 hasConcept C89423630 @default.
• W3120564211 hasConceptScore W3120564211C126322002 @default.
• W3120564211 hasConceptScore W3120564211C141071460 @default.
• W3120564211 hasConceptScore W3120564211C168563851 @default.
• W3120564211 hasConceptScore W3120564211C174802600 @default.
• W3120564211 hasConceptScore W3120564211C197934379 @default.
• W3120564211 hasConceptScore W3120564211C2775872228 @default.
• W3120564211 hasConceptScore W3120564211C2776703206 @default.
• W3120564211 hasConceptScore W3120564211C2777052132 @default.
• W3120564211 hasConceptScore W3120564211C2778980435 @default.
• W3120564211 hasConceptScore W3120564211C2779489039 @default.
• W3120564211 hasConceptScore W3120564211C2780176578 @default.
• W3120564211 hasConceptScore W3120564211C2781413609 @default.
• W3120564211 hasConceptScore W3120564211C501593827 @default.
• W3120564211 hasConceptScore W3120564211C523546767 @default.
• W3120564211 hasConceptScore W3120564211C54355233 @default.
• W3120564211 hasConceptScore W3120564211C71924100 @default.
• W3120564211 hasConceptScore W3120564211C86803240 @default.
• W3120564211 hasConceptScore W3120564211C89423630 @default.
• W3120564211 hasLocation W31205642111 @default.
• W3120564211 hasOpenAccess W3120564211 @default.
• W3120564211 hasPrimaryLocation W31205642111 @default.
• W3120564211 hasRelatedWork W1990669356 @default.
• W3120564211 hasRelatedWork W2002833311 @default.
• W3120564211 hasRelatedWork W2073651855 @default.
• W3120564211 hasRelatedWork W2153012695 @default.
• W3120564211 hasRelatedWork W2155139966 @default.
• W3120564211 hasRelatedWork W2171616719 @default.
• W3120564211 hasRelatedWork W22233518 @default.
• W3120564211 hasRelatedWork W2583670803 @default.
• W3120564211 hasRelatedWork W2818026 @default.
• W3120564211 hasRelatedWork W2741801165 @default.
• W3120564211 isParatext "false" @default.
• W3120564211 isRetracted "false" @default.
• W3120564211 magId "3120564211" @default.
• W3120564211 workType "article" @default.